NYSE:JNJJohnson & Johnson Competitors & Alternatives

UnitedHealth Group (NYSE:UNH) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional and Insider Ownership

86.4% of UnitedHealth Group shares are owned by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are owned by institutional investors. 0.8% of UnitedHealth Group shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

UnitedHealth Group has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Dividends

UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.6%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UnitedHealth Group has increased its dividend for 10 consecutive years and Johnson & Johnson has increased its dividend for 24 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings and Valuation

This table compares UnitedHealth Group and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has lower revenue, but higher earnings than UnitedHealth Group. Johnson & Johnson is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares UnitedHealth Group and Johnson & Johnson's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for UnitedHealth Group and Johnson & Johnson, as reported by MarketBeat.

UnitedHealth Group currently has a consensus price target of $338.4583, indicating a potential upside of 5.02%. Johnson & Johnson has a consensus price target of $164.2667, indicating a potential upside of 9.76%. Given Johnson & Johnson's higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than UnitedHealth Group.

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Pfizer and Johnson & Johnson's net margins, return on equity and return on assets.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.0%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 24 consecutive years.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pfizer and Johnson & Johnson, as reported by MarketBeat.

Pfizer currently has a consensus price target of $38.8583, indicating a potential upside of 1.38%. Johnson & Johnson has a consensus price target of $164.2667, indicating a potential upside of 9.76%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Pfizer.

Risk & Volatility

Pfizer has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Institutional and Insider Ownership

70.2% of Pfizer shares are owned by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Pfizer and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Pfizer has higher earnings, but lower revenue than Johnson & Johnson. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Pfizer on 12 of the 17 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Johnson & Johnson and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.0%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 24 consecutive years and Merck & Co., Inc. has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a summary of recent ratings for Johnson & Johnson and Merck & Co., Inc., as reported by MarketBeat.com.

Johnson & Johnson currently has a consensus price target of $164.2667, indicating a potential upside of 9.76%. Merck & Co., Inc. has a consensus price target of $94.9286, indicating a potential upside of 14.81%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Johnson & Johnson.

Volatility & Risk

Johnson & Johnson has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Institutional and Insider Ownership

68.4% of Johnson & Johnson shares are held by institutional investors. Comparatively, 74.3% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Johnson & Johnson and Merck & Co., Inc.'s revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Merck & Co., Inc.. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Merck & Co., Inc. on 9 of the 16 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Johnson & Johnson and Novartis' net margins, return on equity and return on assets.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Novartis pays an annual dividend of $2.01 per share and has a dividend yield of 2.4%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Novartis pays out 38.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 24 consecutive years and Novartis has increased its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent ratings for Johnson & Johnson and Novartis, as reported by MarketBeat.com.

Johnson & Johnson currently has a consensus price target of $164.2667, indicating a potential upside of 9.76%. Novartis has a consensus price target of $108.00, indicating a potential upside of 27.16%. Given Novartis' higher probable upside, analysts plainly believe Novartis is more favorable than Johnson & Johnson.

Volatility & Risk

Johnson & Johnson has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Institutional and Insider Ownership

68.4% of Johnson & Johnson shares are held by institutional investors. Comparatively, 10.8% of Novartis shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Johnson & Johnson and Novartis' revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Novartis on 14 of the 17 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Insider & Institutional Ownership

68.4% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 73.6% of Abbott Laboratories shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Johnson & Johnson and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Abbott Laboratories. Johnson & Johnson is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Johnson & Johnson has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Profitability

This table compares Johnson & Johnson and Abbott Laboratories' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Johnson & Johnson and Abbott Laboratories, as reported by MarketBeat.

Johnson & Johnson currently has a consensus target price of $164.2667, indicating a potential upside of 9.76%. Abbott Laboratories has a consensus target price of $105.6429, indicating a potential upside of 4.96%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, research analysts plainly believe Johnson & Johnson is more favorable than Abbott Laboratories.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 24 consecutive years and Abbott Laboratories has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Johnson & Johnson beats Abbott Laboratories on 11 of the 17 factors compared between the two stocks.

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Insider & Institutional Ownership

68.4% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 72.4% of AbbVie shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Johnson & Johnson and AbbVie's top-line revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Johnson & Johnson has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Johnson & Johnson and AbbVie's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Johnson & Johnson and AbbVie, as reported by MarketBeat.

Johnson & Johnson currently has a consensus target price of $164.2667, indicating a potential upside of 9.76%. AbbVie has a consensus target price of $107.00, indicating a potential upside of 12.03%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Johnson & Johnson.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 4.9%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. AbbVie pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 24 consecutive years and AbbVie has raised its dividend for 1 consecutive years.

Summary

AbbVie beats Johnson & Johnson on 9 of the 17 factors compared between the two stocks.